57
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      NEuro COgnitive REhabilitation for Disease of Addiction (NECOREDA) Program: From Development to Trial

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Despite extensive evidence for cognitive deficits associated with drug use and multiple publications supporting the efficacy of cognitive rehabilitation treatment (CRT) services for drug addictions, there are a few well-structured tools and organized programs to improve cognitive abilities in substance users. Most published studies on cognitive rehabilitation for drug dependent patients used rehabilitation tools, which have been previously designed for other types of brain injuries such as schizophrenia or traumatic brain injuries and not specifically designed for drug dependent patients. These studies also suffer from small sample size, lack of follow-up period assessments and or comprehensive treatment outcome measures. To address these limitations, we decided to develop and investigate the efficacy of a paper and pencil cognitive rehabilitation package called NECOREDA (Neurocognitive Rehabilitation for Disease of Addiction) to improve neurocognitive deficits associated with drug dependence particularly caused by stimulants (e.g. amphetamine type stimulants and cocaine) and opiates. To evaluate the feasibility of NECOREDA program, we conducted a pilot study with 10 opiate and methamphetamine dependent patients for 3 months in outpatient setting. NECOREDA was revised based on qualitative comments received from clients and treatment providers. Final version of NECOREDA is composed of brain training exercises called “Brain Gym” and psychoeducational modules called “Brain Treasures” which is implemented in 16 training sessions interleaved with 16 review and practice sessions. NECOREDA will be evaluated as an add-on intervention to methadone maintenance treatment in a randomized clinical trial among opiate dependent patients starting from August 2015. We discuss methodological features of NECOREDA development and evaluation in this article.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Functional relevance of cross-modal plasticity in blind humans.

          Functional imaging studies of people who were blind from an early age have revealed that their primary visual cortex can be activated by Braille reading and other tactile discrimination tasks. Other studies have also shown that visual cortical areas can be activated by somatosensory input in blind subjects but not those with sight. The significance of this cross-modal plasticity is unclear, however, as it is not known whether the visual cortex can process somatosensory information in a functionally relevant way. To address this issue, we used transcranial magnetic stimulation to disrupt the function of different cortical areas in people who were blind from an early age as they identified Braille or embossed Roman letters. Transient stimulation of the occipital (visual) cortex induced errors in both tasks and distorted the tactile perceptions of blind subjects. In contrast, occipital stimulation had no effect on tactile performance in normal-sighted subjects, whereas similar stimulation is known to disrupt their visual performance. We conclude that blindness from an early age can cause the visual cortex to be recruited to a role in somatosensory processing. We propose that this cross-modal plasticity may account in part for the superior tactile perceptual abilities of blind subjects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cognitive enhancement as a treatment for drug addictions.

            Drug addiction continues to be an important public health problem, with an estimated 22.6 million current illicit drug users in the United States alone. For many addictions, including cocaine, methamphetamine, and marijuana addiction, there are no approved pharmacological treatments. Behavioral treatments are effective but effects vary widely across individuals. Treatments that are effective across multiple addictions are greatly needed, and accumulating evidence suggests that one such approach may be pharmacological or behavioral interventions that enhance executive inhibitory control in addicts. Current evidence indicates that most forms of chronic drug use may be associated with significant cognitive impairments, especially in attention, working memory, and response inhibition functions. In some studies, these impairments predict poor treatment retention and outcome. A number of cognitive enhancing agents, including galantamine, modafinil, atomoxetine, methylphenidate, and guanfacine, have shown promising findings in human studies. Specific behavioral interventions, including cognitive remediation, also show promise. However, whether improvement of selective cognitive functions reduces drug use behavior remains to be determined. Cognitive enhancement to improve treatment outcomes is a novel strategy worthy of future research, as are related questions such as whether these approaches may be broadly beneficial to most addicts or best reserved for substance users with specific demonstrated cognitive impairments. This article is part of a Special Issue entitled 'Cognitive Enhancers'. Published by Elsevier Ltd.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Addiction and Cognition

              The brain regions and neural processes that underlie addiction overlap extensively with those that support cognitive functions, including learning, memory, and reasoning. Drug activity in these regions and processes during early stages of abuse foster strong maladaptive associations between drug use and environmental stimuli that may underlie future cravings and drug-seeking behaviors. With continued drug use, cognitive deficits ensue that exacerbate the difficulty of establishing sustained abstinence. The developing brain is particularly susceptible to the effects of drugs of abuse; prenatal, childhood, and adolescent exposures produce long-lasting changes in cognition. Patients with mental illness are at high risk for substance abuse, and the adverse impact on cognition may be particularly deleterious in combination with cognitive problems related to their mental disorders.
                Bookmark

                Author and article information

                Journal
                Basic Clin Neurosci
                Basic Clin Neurosci
                BCN
                BCN
                Basic and Clinical Neuroscience
                Iranian Neuroscience Society
                2008-126X
                2228-7442
                October 2015
                : 6
                : 4
                : 291-298
                Affiliations
                [1. ]Translational Neuroscience Program, Institute for Cognitive Science Studies, Tehran, Iran.
                [2. ]Neurocognitive Laboratory, Iranian National Center for Addiction Studies (INCAS), Iranian Institute for Reduction of High-risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
                [3. ]Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran.
                [4. ]Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
                [5. ]Department of Psychiatry, School of Medicine, Yale University, CT, USA.
                [6. ]VA Connecticut Healthcare System, West Haven, CT, USA.
                [7. ]Substance Abuse Prevention and Treatment Office (SAPTO), Mental Health, Social Health and Addiction Department (MEHSHAD), Ministry of Health and Medical Education, Iran.
                [8. ]Clinical Department, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
                [9. ]Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran.
                Author notes
                [* ]Corresponding Author: Hamed Ekhtiari, MD, Address: Neurocognitive Laboratory, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran., Tel: +98 (912) 1885898, Postal Code: 1336616357, E-mail: H_Ekhtiari@ 123456razi.tums.ac.ir
                Article
                bcn-6-291
                4668876
                c4292f5a-1ef8-4b2c-ad7f-8e5e41abf951
                Copyright© 2015 Iranian Neuroscience Society

                This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

                History
                : 12 May 2015
                : 27 August 2015
                : 07 September 2015
                Categories
                Methodological Note

                cognitive enhancers,drug addiction,necoreda,treatment
                cognitive enhancers, drug addiction, necoreda, treatment

                Comments

                Comment on this article